Secunderabad Chronicle

Acute Myeloid Leukemia (AML) Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

 Breaking News
  • No posts were found

Acute Myeloid Leukemia (AML) Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

October 08
05:36 2021
Acute Myeloid Leukemia (AML) Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
DelveInsight Business Research LLP
DelveInsight’s, “Acute Myeloid Leukemia (AML) – Pipeline Insight, 2021,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Acute Myeloid Leukemia (AML) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight’s “Acute Myeloid Leukemia Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Acute Myeloid Leukemia pipeline landscapes. 

The report comprises Acute Myeloid Leukemia pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Acute Myeloid Leukemia therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Acute Myeloid Leukemia pipeline products.    

 

Some of the key takeaways from the Acute Myeloid Leukemia Pipeline Report:

  • Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Actinium Pharmaceuticals, AVEO Oncology, and Biodesix, Rafael Pharmaceuticals, BioSight, BerGenBio, Helsinn Healthcare, etc., are developing therapies for the treatment of Acute Myeloid Leukemia.

  • Emerging therapies such as omab-B CD45 and Actimab-A CD33, Ficlatuzumab, Devimistat, BST236, Bemcentinib, Pracinostat, are expected to have a significant impact on the  Acute Myeloid Leukemia market in the coming years.

Get an overview of pipeline landscape @ Acute Myeloid Leukemia Clinical Trials Analysis  

Acute myelogenous leukemia (AML) is a cancer of the blood and bone marrow — the spongy tissue inside bones where blood cells are made. The word “acute” in acute myelogenous leukemia denotes the disease’s rapid progression. It’s called myelogenous leukemia because it affects a group of white blood cells called the myeloid cells, which normally develop into the various types of mature blood cells, such as red blood cells, white blood cells, and platelets.

Acute Myeloid Leukemia Pipeline Therapies along with Key Players: 

  • Actimab-A CD33 by Actinium Pharmaceuticals, 

  • Ficlatuzumab by AVEO Oncology and Biodesix, 

  • Devimistat by  Rafael Pharmaceuticals,

  • BST236 by BioSight

  • Bemcentinib by BerGenBio

  • Pracinostat by Helsinn Healthcare

  • And others.

Scope of Acute Myeloid Leukemia Pipeline Drug Insight    

  • Coverage: Global 

  • Major Players: Actinium Pharmaceuticals, AVEO Oncology and Biodesix, Rafael Pharmaceuticals, BioSight, BerGenBio, Helsinn Healthcare, and others.

  • Pipeline Therapies: omab-B CD45 and Actimab-A CD33, Ficlatuzumab, Devimistat, BST236, Bemcentinib, Pracinostat, and others.

Table of Contents

1

Acute Myeloid Leukemia Report Introduction

2

Acute Myeloid Leukemia Executive Summary

3

Acute Myeloid Leukemia Overview

4

Acute Myeloid Leukemia- Analytical Perspective In-depth Commercial Assessment

5

Acute Myeloid Leukemia Pipeline Therapeutics

6

Acute Myeloid Leukemia Late Stage Products (Phase II/III)

7

Acute Myeloid Leukemia Mid Stage Products (Phase II)

8

Acute Myeloid Leukemia Early Stage Products (Phase I)

9

Acute Myeloid Leukemia Preclinical Stage Products

10

Acute Myeloid Leukemia Therapeutics Assessment

11

Acute Myeloid Leukemia Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Acute Myeloid Leukemia Key Companies

14

Acute Myeloid Leukemia Key Products

15

Acute Myeloid Leukemia Unmet Needs

16 

Acute Myeloid Leukemia Market Drivers and Barriers

17

Acute Myeloid Leukemia Future Perspectives and Conclusion

18

Acute Myeloid Leukemia Analyst Views

19

Appendix

20

About DelveInsight

Related Reports:

Acute Myeloid Leukemia Market 

DelveInsight’s “Acute Myeloid Leukemia – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Acute Myeloid Leukemia, historical and forecasted epidemiology as well as the Acute Myeloid Leukemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Acute Myeloid Leukemia Epidemiology

DelveInsight’s ‘Acute Myeloid Leukemia – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Acute Myeloid Leukemia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Related Articles